Massachusetts Institute of Technology
Sign in Create Account

What Can We Learn From Related Industries?

08/12/2004 3:15PM Wong Auditorium
Scott Sarazen, Senior Vice President, Life Sciences, MassDevelopment; Andrew Parece, Vice President, Analysis Group/Economics Analysis Group, Inc; Tamsin S. Randlett, Senior Director, Government Affairs, Gap Inc. ; Stephen M. Sammut, Venture Partner, Burrill & Company

Description: In some ways, the pharmaceutical industry is unique from other industries, its upfront R&D costs, for instance are extremely high. But these panelists see some commonalities with other business sectors, and offer observations and counsel to drug manufacturers. Andrew Parece focuses on the trade of high tech goods, such as software, digital cameras and DVDs. There are difficulties controlling the free flow of these goods, and their prices, across borders a challenge the drug industry also confronts today. Parece suggests that pharma companies "leverage their competitive advantage 'to differentiate products, and turn offerings into products and services such as patient assistance and education, and disease management." Tamsin Randlett of Gap, Inc. deals more with issues on the manufacturing end. The Gap outsources clothing production to companies in parts of the world where wage and labor standards lag. To respond to concerns about equity and human rights, Randlett partners with international labor organizations and NGOs. She suggests pharmaceutical industries similarly "leverage world health organizations 'to bring greater credibility to your efforts" and sit down with politicians, even those opposed to industry positions. Stephen Sammut's venture capital group invests in the biosecurity business. Just as in drug manufacturing, biosecurity involves risky and expensive R&D, licensing and liability questions, and unpredictable market size. Since "northern hemisphere concerns about biosecurity are the daily disease burden of many countries in the southern hemisphere," says Sammut, one answer to the pricing problem may be creating drugs useful for both markets simultaneously.

Host(s): Sloan School of Management, MIT Sloan School of Management

Comments (0)

It looks like no one has posted a comment yet. You can be the first!

You need to log in, in order to post comments. If you don’t have an account yet, sign up now!

MIT World — special events and lectures

MIT World — special events and lectures

Category: Events | Updated 5 months ago

Created
December 13, 2011 11:18
Category
Tags
License
All Rights Reserved (What is this?)
Additional Files


Viewed
2058 times

More from MIT World — special events and lectures

Spectacular Reconstructions: Ways of Seeing and the Politics of Recovery in American Urban Disasters

Spectacular Reconstructions: Ways o...

Added over 3 years ago | 01:22:00 | 1965 views

Warning: Physics Envy May be Hazardous to Your Wealth

Warning: Physics Envy May be Hazard...

Added over 3 years ago | 00:57:18 | 8515 views

Energy in a Global Context

Energy in a Global Context

Added over 3 years ago | 01:31:00 | 2683 views

Liberty by Design

Liberty by Design

Added over 3 years ago | 01:26:00 | 7813 views

The Many Facets of NF-Kappa B

The Many Facets of NF-Kappa B

Added over 3 years ago | 00:56:53 | 2156 views

Living with Catastrophic Terrorism: Can Science and Technology Make the US Safer?

Living with Catastrophic Terrorism:...

Added over 3 years ago | 01:23:00 | 2328 views